Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

OpGen — 5 videos in collection

More on this equity

OpGen (Nasdaq CM: OPGN) has announced encouraging top-line data from its Unyvero urinary tract infection (UTI) panel trial.

The Unyvero UTI panel is a diagnostic test designed to detect pathogens and antimicrobial resistance markers related to UTI from native urine specimens without the need for culturing, bringing test times down to less than five hours.

In this video, Edison Group Managing Director, Soo Romanoff and OpGen’s CEO, Oliver Schacht, discuss the significance of the trial data and OpGen’s future plans.

< Previous
Next >

You may also be interested in these:

Healthcare

OpGen: Edison Open House Healthcare 2022

Healthcare

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free